About the Journal

The Drug Development and Therapeutics (DDT) is an open-access peer-reviewed journal committed to publishing high-quality articles in the field of Drug synthesis and development and Therapeutics from industry, Clinicians and Academia. The journal is owned by the Organization of Pharmaceutical Unity with BioAllied Sciences (OPUBS) and published by the Scientific Scholar.

Audience

Our audience includes Drug Development and Therapeutics also including Natural products, Target validation, Targeted drug discovery, High-throughput screening, Combinatorial chemistry, and library design, Drug delivery, ADME/Tox, PK/PD, Pharmacology, Pharmaceutical formulation, Genomics and proteomics, molecular modeling, Bioinformatics, Vaccines, Clinical trial evaluations. Pharmaceutical sciences, medicinal/analytical sciences, Biotechnology, Bioallied Sciences.

Review Process

The Drug Development and Therapeutics (DDT) has a highly rigorous double-blinded peer-review process that makes sure that manuscripts are scientifically accurate, relevant, novel and important. Authors disclose all conflicts of interest, affiliations and financial disclosures such that the published content is not biased.

In-house submissions that contain the work of any editorial board member, are not allowed to be reviewed by that editorial board member and all decisions regarding this manuscript are made by an independent editor. In addition, these manuscripts are reviewed by the two external reviewers. This is also disclosed in the published manuscript under the section of Conflict of Interest.

Editorial Team

The editorial board comprises a panel of experts in Drug synthesis and development and Therapeutics from industry, Clinicians and Academia from various countries to provide their expertise and guidance to the Editor-In-Chief in maintaining the clarity of content and focus of the journal’s purpose.

About the Editor

Chief Patron

Raid Alany, PhD
Kingston University, London, UK

Editor-in-Chief

Hazrina Hadi, PhD
Faculty of Pharmacy,
International Islamic University of Malaysia,
Pahang, Malaysia

Assistant Editor

Himanshu Gupta, M. Pharm, PGDIB, PhD
The University of Toledo,
OH, USA

Facts about the Journal

The Drug Development and Therapeutics (DDT) is a peer-reviewed international journal with a double-blind review process. Its frequency of publication is quarterly. The Drug Development and Therapeutics (DDT) is published in E-Journal format and the journal is also available in print on demand.

Benefits

A manuscript published in the Drug Development and Therapeutics (DDT) can be read and downloaded by readers all over the world without any charges or fees. The author retains the copyright of the manuscript and the figures. This allows authors to extend their exposure in the world of medical research and get worldwide recognition for their work.

Abstracting and Indexing Information

EBSCO Publishing Electronic Databases

Journal Ethics

The Drug Development and Therapeutics (DDT) is committed to meeting and upholding ethical guidelines at all stages of the publication process. We follow the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE), and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit our Ethical Guidelines Section.

Plagiarism Policy

We provide plagiarism check software (iThenticate) on the Editor’s and Reviewer’s panel in the manuscript management system. We encourage our editors and reviewers to use the plagiarism check. The manuscript’s found to have plagiarism is rejected.

Archival Policy

We use PORTICO for our third-party repository for all articles published with us. All our manuscripts are assigned a DOI number from CROSSREF, and we are members of Crossref ( https://crossref.org).

Open Access Publication and Creative Commons Licensing

Drug Development and Therapeutics is an open-access journal, and manuscripts published are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License (CC-BY-NC-SA 4.0), which allows others to remix, transform, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Ahead of Print policy

Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. The Drug Development and Therapeutics (DDT) has a policy that changes will not be made after publication of an article without following accepted procedures for making corrections to the scientific record.

Subscription Information

The Drug Development and Therapeutics (DDT) is a quarterly publication and published manuscripts in the journal can be read and downloaded by readers all over the world without any charges or fees.

The journal is published in E-Journal format and the journal is also available in print on demand. Journal also offers a Print-on-Demand subscription – https://scientificscholar.com/buy-subscriptions/.

Publisher

Scientific Scholar LLC (scientificscholar.com) is a well-respected medical publisher that fully supports open access publishing models, Subscription and Society based journal models through its own in-house peer-review management system – EditorialAssist (journalmanagement.org). The head office of Scientific Scholar is in Rochester, NY, USA and has a subsidiary arm in India.

The mission of the Scientific Scholar is “Share, Learn and Improve”.